About Cabotegravir,Rilpivirine Hydrochloride
            
            Class: | Antiretroviral agent (Integrase Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor)  
Use: | Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg as part of a complete regimen  
Adult dose: | 600 mg Cabotegravir and 900 mg Rilpivirine administered as an intramuscular injection once monthly or every two months, depending on the regimen  
Pediatric dose: | Not established for patients weighing less than 35 kg; dosing for patients 35 kg and above 
         
        
            
                
                
                    
                        Drug Class
                    
                    Antiretroviral agent (Integrase Inhibitor and Non-Nucleoside Reverse Transcriptase Inhibitor)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg as part of a complete regimen
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F); do not freeze; can be stored at room temperature (up to 25°C or 77°F) for up to 30 days
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: VIIV healthcare L.L.C., Canada
                    
                    
                    Package Size
                    1 kit 2ml each (400/600)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 5165.78
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        600 mg Cabotegravir and 900 mg Rilpivirine administered as an intramuscular injection once monthly or every two months, depending on the regimen
                    
                    
                        Pediatric Dose
                    
                    
                        Not established for patients weighing less than 35 kg; dosing for patients 35 kg and above is the same as adults
                    
                 
                
                
                    
                        Side Effects
                    
                    Injection site reactions, headache, fatigue, nausea, diarrhea, and fever
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Known hypersensitivity to Cabotegravir, Rilpivirine, or any component of the formulation; use with certain medications that are contraindicated due to significant drug interactions
         
        
        
            
                Important Warnings
            
            Risk of serious allergic reactions, hepatotoxicity, and potential for drug interactions; not recommended for use in patients with active hepatitis B or C infection without appropriate monitoring and management
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.